WO2017078563A1 - Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения - Google Patents
Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения Download PDFInfo
- Publication number
- WO2017078563A1 WO2017078563A1 PCT/RU2015/000738 RU2015000738W WO2017078563A1 WO 2017078563 A1 WO2017078563 A1 WO 2017078563A1 RU 2015000738 W RU2015000738 W RU 2015000738W WO 2017078563 A1 WO2017078563 A1 WO 2017078563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- stromal
- cell
- fraction
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/02—Means for pre-treatment of biological substances by mechanical forces; Stirring; Trituration; Comminuting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/05—Means for pre-treatment of biological substances by centrifugation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/04—Cell isolation or sorting
Definitions
- the present group of inventions relates to medical biotechnology and cell technology and is intended for the isolation of cell fractions from human and animal tissues, namely the isolation of the stromal-vascular fraction of adipose tissue.
- Subcutaneous fat is an alternative bone marrow source of stem and progenitor cells for regenerative medicine.
- the main advantage of adipose tissue is the low invasiveness of the sampling procedure, minimal pain, discomfort and risk to the patient.
- Adipose tissue provides a significantly larger number of stem cells compared to bone marrow.
- the bone marrow transplant contains 0.006 - 0.06 x 10 6 stem cells per 100 ml, and the number of viable stem and progenitor cells in the adipose tissue fraction is approximately 0.5 x 106 to 20 x 10 6 cells per 100 ml of tissue.
- the stromal-vascular fraction is characterized by significant heterogeneity and variability of the cellular composition depending on the condition of the donor, its age and the place of collection of biological material. After sorting, cell populations can be isolated from the stromal-vascular fraction: endothelial and smooth muscle cells, pericytes, fibroblasts, mast cells and preadipocytes.
- cells of the regenerative fraction namely, a complex of stem and progenitor cells of adipose tissue (adipose derived stem cells, ADSCs).
- ADSCs have significant potential for differentiation into adipocytes, chondrocytes and osteoblasts, myocytes, neuronal cells, cardiomyocytes and hepatocytes.
- the clinical use of the stromal-vascular fraction includes the regeneration of soft tissues and bones, cosmetic defects, chronic trophic and radiation ulcers, burns, Crohn's disease, multiple sclerosis, in the graft versus host reaction, in myocardial infarction and strokes of various origins.
- the main advantages of using this type of cell are easy access to the source of cells, a large number and high yield per unit volume of tissue, high multipotency, comparable efficiency and safety regarding bone marrow mesenchymal cells.
- the lipoaspiration procedure is widely used, standardized, easy to perform in the conditions of the treatment room and can be carried out in a short time - about 90 minutes.
- cell fractions isolated from adipose tissue can be advantageously used for clinical practice, including, excluding the stage of cultivation.
- a known method of isolating stem cells from adipose tissue using the manual method (Zuk P.A., Zhu M., Mizuno N. et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7 ( 2): 211-28.).
- This method is based on the treatment of lipoaspirate with a 0.075% type I collagenase solution at 37 ° C for 30 minutes and subsequent centrifugation of the resulting suspension at 800 d.
- the cell suspension After centrifugation, the cell suspension is divided into two fractions: adipocytes are in the upper layer and the sediment is in the sediment - stromal-vascular fraction with an admixture of red blood cells, which were removed during incubation in a lysis solution of ammonium chloride.
- the disadvantages of this method are the high time and organizational costs, the presence of the "human factor”, a high risk of impaired sterility of the process and contamination of biological material and the final product.
- a device is known from the prior art (System for processing lipoaspirate cells EP 1921133 A2, CYTORI THERAPEUTICS, INC (US), IPC A61K31 / 436, published May 14, 2008), which is a closed system for processing lipoaspirate obtained during liposuction.
- the system connects directly to the lipoaspiration cannula. It includes a vacuum pump, a container for collecting lipoaspirate, a mixer for mixing the processed biomaterial with additives and activators, a system of two filters with pores of different diameters.
- the first filter divides the lipoaspirate into 2 fractions, where one fraction contains a population of cells, including stem cells of adipose tissue, and the other fraction contains lipids, blood, adipocytes and saline.
- the first filter rotates and structurally divides the container into two chambers, for the corresponding fractions, and the second filter concentrates the cell fraction before being fed to the mixer.
- the conductive line allows you to extract the final fraction without violating the tightness of the system and direct it to a centrifuge, then extract the obtained fraction aseptically.
- the device allows you to enter activators and additives.
- the system also has a built-in temperature controller.
- the main disadvantage of this device is that at the first stage of processing, the lipoaspirate is filtered without providing destruction of the stroma of the tissue, which fixes the cells of the stromal-vascular fraction and does not allow them to pass through the filter, thereby reducing the concentration of cells in the permeate. Also, the shortcomings of the system are long trunk lines and a significant number of junctions, which are an environment for adhesion and loss of target cells.
- a device is known from the prior art (Method and Apparatus for Separating a Material, US20110251041 A1, BIOMET BIOLOGICS, LLC (US), IPC B04B1 / 08, published October 13, 2011), which is a system for separating multicomponent material, at least into two fractions.
- This device is a container in the form of a hollow cylinder divided by a valve into two parts unequal in volume. The function of the valve is to differentiate fractions of different densities.
- the system contains a settling tank at the base of the design with inclined walls, separated by a valve from the main chamber volume.
- the valve has a conical surface, includes an insert, also having a conical surface, between the side wall and the longitudinal axis of the cylinder, the conical surface is turned downward.
- the valve contains a disk with round holes and sector shapes.
- the valve includes a flexible membrane that activates it with increasing hydraulic pressure during centrifugation; when the disk is rotated, the holes are matched, ensuring valve permeability.
- the system is additionally equipped with a grinder and a vacuum pump in communication with the separation chamber. In this case, adipose tissue is divided into three fractions. The first fraction is isolated between the valve and the bottom of the chamber and contains cellular material. The second fraction is isolated between the valve and the upper end of the chamber and contains fat.
- the third fraction is isolated between the components of the valve and includes a tumescence fluid.
- the main disadvantage of this system is the possibility of filling elements of a mechanical device with tissue fragments, which entails the risk of device failure, contamination of the final fraction with components of the original biomaterial. Processing without ensuring the destruction of the stroma of the tissue, which fixes the cells of the stromal-vascular fraction and does not allow them to pass through the filter, thereby reducing the concentration of cells in the permeate.
- a device is known from the prior art (Regenerative cell extraction device WO 2013183797 A1, HURIMBIOCELL CO., LTD (KR), IPC C12M1 / 10, published 12.12.2013), which is a container with a cone-shaped bottom and a rotating longitudinal axis driven by an external motor. A product consisting of many petals is fixed on the axis, which has a direct effect on the lipoaspirate.
- the tank is equipped with a pipe for introducing biomaterial and isolating the tissue fraction containing stem cells.
- a prior art device is known (Device for separating adult stem cell US 20130344589 A1, HUMAN MED AG (DE), IPC C12M1 / 00, published December 26, 2013), which is a system including an adipose tissue container equipped with a device for feeding liquids for washing biomaterial, a mixture of necessary reagents, alternately with extracting the fraction containing stem cells, a valve for equalizing pressure, a piston, a vibrator, a semi-permeable membrane having an electrostatic charge and a valve that divide the container into 2 parts, with a temperature controller atura.
- One of the chambers is equipped with a device for mixing the initial biomaterial with additives, performing rotational and / or pendulum movements.
- the main disadvantage of this device is the method of creating pressure due to the piston, which leads to a high mechanical load on the target cells due to punching through the filter and edge destruction of the cells at the junction of the piston to the cylinder wall.
- a device for the isolation of adipose stem cells (System and methods for preparation of adipose-derived stem cells, US 20130012921 A1, PUSTILNIK FELIX, IPC A61M37 / 00, publ. 10.01.2013), which is a cone-shaped container, hermetically closed, is selected as a prototype a lid equipped with connectors for the introduction and removal of biomaterial and liquids for its processing, as well as an auxiliary tube for the concentration obtained from the stromal-vascular fraction.
- the disadvantages of this system are the presence of two test tubes, which increases the risk of contamination of the material, its loss when transferred between containers, entails additional requirements for auxiliary equipment.
- the general technical task of this group of inventions is to increase the efficiency and safety of the method for isolating cells, expanding its functionality and optimizing the isolation procedure.
- the overall technical result of the proposed group of inventions is the controlled release of the stromal-vascular fraction of adipose tissue, characterized by high cell survival, lack of debris, residues of stromal and adipose tissue and circulating blood cells, low concentration and activity of residual enzymes.
- the stated technical problem is achieved due to the presence in the device of two chambers separated by a system of microfilters with different pore diameters; the presence of isolated channels in the wall of the system; the presence of valves on the adapter fittings for introducing biological material, introducing reagents and washing buffer, selecting debris and adipose tissue stroma residues, and selecting the final product; the use of release treatment of the inner surface of the device and use for filling and selection of the biological material of the syringe Luer-lock with an elongated nose and an enlarged piston handle.
- the proposed device is a closed airtight system in the form of a transparent cone-shaped container with a volume of 150 - 300 ml, with external graduation by volume, a system of channels and fittings-adapters having Luer-Lock connectors, the container is divided by a multilayer filter into two chambers - a working chamber for treating tissue and a chamber for concentrating cells, the working chamber having a volume of 145-299 ml, and the chamber for concentrating having a volume of 1-5 ml.
- the filter system is a complex of at least 2 nylon filters with a diameter of 10 microns for the lower filter to 500 microns for the upper filter, separated by polymer gaskets and placed in a polymer housing having levers on its circumference and a locking element for bayonet connection with capacity.
- the filter system is installed in a container in a silicone gasket by means of a bayonet connection, for this the connection point between the filter and the container has sector grooves.
- the cone-shaped shape of the tissue processing container and its separation into two chambers by a microfilter system with a pore diameter of 10-500 microns provides an increase in the efficiency, safety and economy of the cell isolation method.
- the device has insulated channels located in the side walls of the tank, and the input of each channel has recesses and sectoral grooves for bayonet connection with adapter fittings.
- the device has a channel for introducing biological material, ending with a groove-recess in the working chamber for processing tissue.
- the device has a channel for introducing reagents and wash buffers, ending with a groove-recess in the working chamber for processing tissue.
- the device has a channel for sampling the supernatant containing cell debris, the remains of untreated stromal and adipose tissue, ending at the place of attachment of the filter in the working chamber for processing tissue.
- the device has a channel for the selection of the final product - the stromal-vascular fraction of adipose tissue, ending at the base of the container in the cell concentration chamber.
- the device may have additional channels for introducing or selecting components ending in a working chamber for processing tissue and / or in a chamber for concentrating cells.
- the device has a bacteriological filter to equalize the pressure inside the system.
- the device has a cover, and the cover around its circumference has locking elements and is connected to the container through a silicone gasket using a bayonet mount or thread.
- the device cover may have openings for each of the channels and the bacteriological filter.
- the lid can be connected to the container through a silicone gasket using steel bolts; for this, the container has corresponding threaded holes.
- the device has adapter fittings for each channel.
- Each adapter fitting has a check valve.
- Each adapter fitting has a Luer-Lock type thread for connection to a syringe.
- Each adapter fitting has a screw cap.
- Each adapter nipple has silicone gaskets to ensure tightness when connected to a container.
- Each adapter nipple has a locking element for connection to the container.
- Each adapter nipple is connected to the tank through the cap and silicone gasket via a bayonet fitting.
- the device may have a casing-cover, and the casing-cover is connected to the tank through the bayonet connection or thread.
- the device may have legs in the form of blades, which are a stand for the container.
- the device may have grooves for fastening to the bucket-rotor of the centrifuge.
- the device is equipped with internal steel reinforcement along the grooves.
- the inner surface of the device is covered with an organosilicon and / or agarose film in order to impart hydrophobic and anti-adhesive properties to the surface.
- an organosilicon and / or agarose film in order to impart hydrophobic and anti-adhesive properties to the surface.
- the sterile and fat-free system is dried and the internal surfaces of the system and channels are treated with a 0.1-10% solution of polydimethylsiloxane in chloroform and / or a 0.1-5% agarose solution.
- the treated system is placed for 1-5 hours in an oven at a temperature of 100 ° C to 300 ° C.
- the device may have a Luer-Lock syringe (not shown in the drawings) with a volume of 50-200 ml with an elongated nose, a screw cap and an enlarged piston handle for introducing biological material and selecting the supernatant and the final product.
- a Luer-Lock syringe (not shown in the drawings) with a volume of 50-200 ml with an elongated nose, a screw cap and an enlarged piston handle for introducing biological material and selecting the supernatant and the final product.
- All components of the device including the container, cover, adapter fittings, adapter nozzle covers, filter system housing and filter system gaskets are made of polycarbonate and / or polypropylene and / or polyethylene and / or fluoroplastic. Gaskets and valves are made of silicone and / or rubber.
- the method for isolating the stromal-vascular fraction of adipose tissue from the lipoaspirate of the present invention includes the following steps:
- the decantation being carried out within 10 to 30 minutes, moreover, the lipoaspirate is washed with physiological saline and / or Hanks balanced salt solution and / or Eagle’s medium in the Dulbecco modification at a temperature of 37 ° C, and the lipoaspirate is washed 1 - 5 times;
- washing the final product from residues of enzymes moreover, washing is carried out with physiological saline and / or Hanks balanced salt solution and / or Eagle’s medium in the Dulbecco modification at a temperature of 37 ° C, moreover, washing of the final product is carried out 1-5 times;
- the introduction of biological material and the selection of biological material from the device is carried out using a syringe for the introduction and selection of biological material.
- the isolated stromal-vascular fraction of adipose tissue can be used in biology and medicine as a cell element for creating tissue-engineering structures based on synthetic and natural materials.
- the isolated stromal-vascular fraction of adipose tissue can be used in biology and medicine for use as a cell autograft to replace and regenerate defects in hard and soft tissues by introducing the stromal-vascular fraction of adipose tissue into hard and / or soft tissues
- the biological tissue placed in the system is washed from the remnants of the circulating blood; subjected to enzymatic treatment with a mixture of collagenases I and II, thermolysin, dispase and trypsin, due to which the stromal tissue is lysed and the stromal-vascular fraction enters the medium.
- the next step is the separation of the cellular component and the remains of stromal and adipose tissue by centrifugation through a filter system with different pore sizes, followed by washing the cell fraction from residual enzymes and concentrating it. Due to the treatment of the inner surface with anti-adhesive media, the remains of the circulating blood and the cell fraction do not stick to the walls of the system and are completely washed during the procedure.
- stromal tissue lysis occurs and the stromal-vascular fraction enters the medium. Due to the presence of a filter system with different pore diameters, the optimal selection of the cell fraction occurs without impurities of stromal and adipose tissue.
- the presence of input / output channels with outputs at different levels inside the system wall allows minimizing the total area of the internal surface of the system, which reduces the risk of cell adhesion on the tube surface; It allows the controlled wall-wise introduction of biological material and reagents, which reduces the physical effect on the biological material and increases the degree of cell survival; allows you to fully select the supernatant with the remains of the stroma of adipose tissue, without affecting the sediment; allows you to fully select the sediment in the form of a stromal-vascular fraction of adipose tissue.
- the presence of inlet valves on the channels ensures the sterility of the processes occurring inside the system.
- the use of transparent plastic as the main material allows you to visually control the process of cell isolation, the introduction of biological material and reagents, the selection of the supernatant with the remains of stromal and adipose tissue, and the selection of the final stromal-vascular fraction.
- the presence of graduation on the surface of the system allows you to visually control the amount of introduced biological material and reagents.
- the use of a syringe with an elongated nose makes it possible to conveniently introduce and select biological material and reagents without the risk of contamination of the material and spillage of liquids outside the system.
- the stromal-vascular fraction of adipose tissue isolated using the claimed invention can be used to create tissue-engineering structures based on synthetic and natural materials; for use as a cell autograft; as a method of treating, repairing or replacing tissue, comprising introducing the stromal-vascular fraction of adipose tissue into hard and / or soft tissues.
- FIG. 1 - shows a device for the isolation of cell fractions from human and animal tissues in an expanded form.
- FIG. 2 - shows a device for isolating cell fractions from human and animal tissues in a detailed sectional view.
- FIG. 3 - shows a device for isolating cell fractions from human and animal tissues in assembled form.
- FIG. 4 - shows a device for the isolation of cell fractions from human and animal tissues in assembled form in a section.
- FIG. 5 - shows a device for isolating cell fractions from human and animal tissues (top view).
- FIG. 6 - depicts a monolayer of cells in the culture of pO (passage Ns1), 5th day. Phase contrast (magnification x10).
- FIG. 7 - depicts a monolayer of cells in culture p1 (passage N ° 1), 5th day.
- Fig 1. shows a device for isolating cell fractions from human and animal tissues in expanded form
- Fig 2 shows a device in expanded form in section
- Fig 3 shows the device in assembled form
- Fig 4 shows a device in assembled form in section
- Fig. 5 shows a device (top view).
- Fig.6 a micrograph of a monolayer of cells in a pO culture (passage N ° 1), day 5, is shown.
- Phase contrast X10 magnification in Fig.7. micrograph of a monolayer of cells in culture p1 (passage N ° 1), day 5 is shown.
- a device for isolating cell fractions from human and animal tissues is a closed airtight system in the form of a transparent cone-shaped container (A) with external calibration in volume (3), a combination of channels (2.1, 2.2, 2.3, 2.4) and adapter fittings (1 ) having connectors of the Luer-Lock type fixed in a transparent cover-case (C) by means of a bayonet connection (4); moreover, the container is divided by a system of microfilters (D) into two chambers - a working chamber for tissue processing (B) and a chamber for concentrating cells (E).
- D system of microfilters
- the microfilter system is a combination of at least two nylon microfilters (9) separated by polymer gaskets (10) and placed in a polymer housing containing the upper part - a silicone gasket (8) and a base (11), which has levers on its circumference and locks an element (12) for connecting to the tissue processing chamber (B) and the cell concentration chamber (E).
- the microfilter system is installed in a container in a silicone gasket (8).
- the device has isolated channels (2.1, 2.2, 2.3, 2.4) located in the side walls of the tank, and the input of each channel has recesses and sectoral grooves (not shown in the device drawings) for bayonet connection with adapter fittings.
- the device has a bacteriological filter (5) for balancing the pressure inside the system.
- the device has a cover (F) with at least one hole, and the cover around its circumference has locking elements and is connected to the container through a silicone gasket (7) by means of a bayonet connection or thread (13).
- the device has adapter fittings (1) for each of the channels.
- the device has a stand-casing (C) with legs in the form of blades (6).
- the operation of the device is a process of stepwise washing and treating adipose tissue with proteolytic enzymes in order to isolate the stromal-vascular fraction, where adipose tissue - lipoaspirate is introduced into the device - a sealed container (A), namely, into the tissue processing chamber (B) through channel (2.1), by connecting a syringe with biological material to the adapter fitting (1).
- adipose tissue - lipoaspirate is introduced into the device - a sealed container (A), namely, into the tissue processing chamber (B) through channel (2.1), by connecting a syringe with biological material to the adapter fitting (1).
- Biological tissue is washed off from the remnants of blood in a buffer solution introduced through a channel (2.2). Excess fluid is removed from the system through the channel (2.4).
- Biological tissue is subjected to enzymatic treatment with a mixture of proteolytic enzymes introduced through the channel (2.2).
- the device is centrifuged in which the stromal-vascular fraction passes through a microfilter system (D) into the cell concentration chamber (E). Excess liquid is removed through channel (2.3), the precipitate is washed off from the residual enzymes with a buffer solution. The final stromal-vascular fraction is taken through the channel (2.4).
- the lipoaspirate was collected in syringes of the type with a Luer-Lock lock with a volume of 50 ml.
- a lipoaspirate in a volume of 100 ml was carefully introduced along the wall into the system into the tissue processing chamber (B) through the channel (2.1), by connecting a syringe (not shown) to the adapter fitting (type 1) and tightly closed the adapter nozzle cover.
- Hanks balanced salt solution was introduced in a volume of 100 ml through the channel (2.2) by connecting the syringe with a buffer (not shown in the figure) to the adapter nozzle (type 1) and tightly closed the adapter nozzle cover.
- the system was placed in a temperature-controlled chamber at 37 ° C with a shaker with a rotation speed of 100-150 rpm for 15-20 minutes for washing the biological material.
- the system was centrifuged at 500 g for 10 minutes. Without turning the system over, using a syringe, a sediment was carefully taken through a channel (2.4) in a volume of 100 ml and the lid was tightly closed. The washing cycle was repeated three times.
- a mixture of collagenase I, collagenase II, thermolysin, dispase and trypsin in a total volume of 10 ml was introduced through the channel (2.2) by connecting a syringe (not shown) to the adapter fitting (type 1) and tightly closed the adapter nozzle cover.
- Hanks balanced salt solution was introduced in a volume of 90 ml through the channel (2.2) by connecting a syringe (not shown) to the adapter fitting (type 1) and tightly closing the adapter nozzle cover.
- the system was placed in a temperature-controlled chamber at 37 ° C with a shaker with a rotation speed of 100-150 rpm for 45 minutes for the enzymatic treatment of biological material.
- the system was centrifuged at 1000 g for 30 minutes. Not turning the system over, using a syringe, carefully selected impurities of fat, stroma, debris and red blood cell residues through a channel (2.3) in a volume of 190 ml, by connecting a syringe (not shown in the figure) with an adapter fitting (type 1) and tightly closed the adapter nozzle cover. Hanks balanced salt solution was introduced in a volume of 190 ml through the channel (2.2) by connecting a syringe (not shown in the figure) to the adapter nozzle (type 1) and tightly closed the adapter nozzle cover. The system was centrifuged at 1000 g for 5 minutes. The washing procedure was repeated three times.
- the obtained primary stromal-vascular fraction cell culture was characterized by cell viability and expression of surface markers - CD90, CD105, CD73, CD34, CD11b, CD19, CD45, CD44 immediately after isolation, in the first and second passages.
- At least 100,000 events for each sample were analyzed. After processing and centrifuging the cell suspension according to the protocol, an analysis of direct (FSC) and lateral (SSC) light scattering was performed in order to determine the size of the studied objects and the presence of intracellular inclusions.
- FSC direct
- SSC lateral
- the isolated fraction is characterized by “purity” of events and a low content of takes and debris.
- the lymphocyte-monocytic gate and the target cell fraction were determined. So, it was shown that for 47,264 events, individual cells accounted for 92%, which in absolute terms amounts to 43,487 events; duplicates (adherent cells) - 1, 4%, and debris (cell debris in the sample) and red blood cells only 6.2%.
- the lymphocytic-monocytic gate was 91.8%, and the target fraction was 7.5%.
- the total concentration of stromal-vascular fraction cells in the sample in terms of unit volume was 66,000 cells per 100 ⁇ l.
- CD 90 positive cells 0.24% CD105 positive cells, at least 0.01% CD44 positive cells.
- Endoglin expression (CD 105) is characteristic of MSCs after passaging, however, this marker can also be expressed on progenitor cells - “mesenchymoangioblasts”. Thus, the percentage of regenerative cells in the selected stromal-vascular fraction is 0.5%.
- a device for isolating cell fractions from human and animal tissues comprising a sealed container for processing tissue with a system of channels and adapter fittings, in which, according to the invention, the container for processing tissue has a cone shape and is divided into two chambers by a microfilter system with a diameter pores of 10 - 500 ⁇ m, hermetically secured with a bayonet connection through a silicone pad, with one chamber serving to treat tissue and the other to concentrate cells, the container being covered with the inner surface is hydrophobic release coating, and to minimize the inner surface area has channels located in the thickness of the vessel wall, one of the channels goes into the tissue processing chamber and the other into the cell concentration chamber, and has a bacteriological filter to equalize the pressure.
- Also described above is a method for isolating cell fractions from human and animal tissues using the proposed device, which includes decantation of lipoaspirate; delicate washing of lipoaspirate in buffer solutions; enzymatic treatment using a mixture of collagenases, thermolysin, dispase and trypsin at 37 ° C; centrifugation at 500 - 2000 g and filtration through microfilters with a pore size of 10 - 300 microns, followed by removal of admixtures of fat and stromal tissue; secondary washing and concentration of cell fraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Mechanical Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES15907892T ES2837096T3 (es) | 2015-11-03 | 2015-11-03 | Dispositivo para aislar fracciones celulares de tejidos humanos y animales y procedimiento para su uso |
IL259095A IL259095B (en) | 2015-11-03 | 2015-11-03 | A device for isolating cell segments from human and animal tissues and a method for using it |
PL15907892T PL3372669T3 (pl) | 2015-11-03 | 2015-11-03 | Urządzenie do izolowania frakcji komórkowych z tkanek ludzkich i zwierzęcych i sposób jego stosowania |
PCT/RU2015/000738 WO2017078563A1 (ru) | 2015-11-03 | 2015-11-03 | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения |
KR1020187015690A KR102143286B1 (ko) | 2015-11-03 | 2015-11-03 | 인간 및 동물 조직으로부터 세포 분획을 단리하기 위한 장치 및 그 사용 방법 |
EP15907892.2A EP3372669B1 (en) | 2015-11-03 | 2015-11-03 | Device for isolating cell fractions from human and animal tissues and method for the use thereof |
EA201891056A EA037537B1 (ru) | 2015-11-03 | 2015-11-03 | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2015/000738 WO2017078563A1 (ru) | 2015-11-03 | 2015-11-03 | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017078563A1 true WO2017078563A1 (ru) | 2017-05-11 |
WO2017078563A8 WO2017078563A8 (ru) | 2018-05-17 |
Family
ID=58662531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2015/000738 WO2017078563A1 (ru) | 2015-11-03 | 2015-11-03 | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP3372669B1 (ru) |
KR (1) | KR102143286B1 (ru) |
EA (1) | EA037537B1 (ru) |
ES (1) | ES2837096T3 (ru) |
IL (1) | IL259095B (ru) |
PL (1) | PL3372669T3 (ru) |
WO (1) | WO2017078563A1 (ru) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019068271A1 (en) * | 2017-10-03 | 2019-04-11 | Bellemed Innovations S.R.O. | DEVICE FOR SEPARATING FLUID BIOLOGICAL MATERIAL, SEPARATION FLOAT AND KIT |
WO2021214159A1 (en) | 2020-04-22 | 2021-10-28 | Cellunite Gmbh | System and method for automated cell processing |
WO2021214162A1 (en) | 2020-04-22 | 2021-10-28 | Cellunite Gmbh | Modular cell processing |
WO2023001910A1 (en) | 2021-07-23 | 2023-01-26 | Cellunite Gmbh | System and method for cell processing |
CN117305077A (zh) * | 2023-09-25 | 2023-12-29 | 成都赛恩吉诺生物科技有限公司 | 一种全封闭式组织解离方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202000002599A1 (it) * | 2020-02-10 | 2021-08-10 | Promoitalia Group Spa | “siringa dotata di mezzi per la separazione selettiva dei componenti di una miscela eterogenea multifase, in particolare delle cellule staminali derivate da tessuto adiposo, kit relativo, e metodo per il suo impiego” |
KR102566931B1 (ko) * | 2020-07-23 | 2023-08-16 | 주식회사 퍼비스코리아 | 줄기세포 분리용 다단 세척제 용기, 이를 포함하는 다단 줄기세포 분리장치 및 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5372945A (en) * | 1985-06-06 | 1994-12-13 | Alchas; Paul G. | Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endothelial cell product |
US20010047966A1 (en) * | 1991-12-02 | 2001-12-06 | Qiagen Gmbh | Process and a device for the isolation of cell components such as nucleic acids from natural sources |
RU2252252C1 (ru) * | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Способ выделения мезенхимальных стволовых клеток |
WO2012148350A1 (en) * | 2011-04-29 | 2012-11-01 | General Electric Company | Automated systems and methods for isolating regenerative cells from adipose tissue |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008027146B4 (de) * | 2008-06-02 | 2012-01-19 | Ing. Erich Pfeiffer Gmbh | Austragvorrichtung |
WO2013106655A1 (en) * | 2012-01-11 | 2013-07-18 | The Gid Group, Inc. | Method for processing adipose tissue and processing apparatus |
EP2834344B1 (en) * | 2012-09-06 | 2016-07-20 | The GID Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
US10336980B2 (en) * | 2013-09-05 | 2019-07-02 | The Gid Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
-
2015
- 2015-11-03 EA EA201891056A patent/EA037537B1/ru unknown
- 2015-11-03 PL PL15907892T patent/PL3372669T3/pl unknown
- 2015-11-03 WO PCT/RU2015/000738 patent/WO2017078563A1/ru active Application Filing
- 2015-11-03 ES ES15907892T patent/ES2837096T3/es active Active
- 2015-11-03 EP EP15907892.2A patent/EP3372669B1/en active Active
- 2015-11-03 KR KR1020187015690A patent/KR102143286B1/ko active IP Right Grant
- 2015-11-03 IL IL259095A patent/IL259095B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5372945A (en) * | 1985-06-06 | 1994-12-13 | Alchas; Paul G. | Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endothelial cell product |
US20010047966A1 (en) * | 1991-12-02 | 2001-12-06 | Qiagen Gmbh | Process and a device for the isolation of cell components such as nucleic acids from natural sources |
RU2252252C1 (ru) * | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Способ выделения мезенхимальных стволовых клеток |
WO2012148350A1 (en) * | 2011-04-29 | 2012-11-01 | General Electric Company | Automated systems and methods for isolating regenerative cells from adipose tissue |
Non-Patent Citations (4)
Title |
---|
GIMBLE J.M. ET AL.: "Concise Review: Adipose-Derived Stromal Vascular Fraction Cells and Stem Cells: Let's Not Get Lost in Translation", STEM CELLS, vol. 29, no. 5, 19 April 2011 (2011-04-19), pages c749 - 754, XP055382306 * |
KOPTEVA V. B.: "Opory vertikalnykh i gorizontalnykh apparatov", METODICHESKIE UKAZANIA, 2005, pages 1, 2, XP009506403 * |
See also references of EP3372669A4 * |
YUAN S. ET AL.: "Evaluation of embryonic age and the effects of different proteases on the isolation and primary culture of chicken intestinal epithelial cells in vitro", ANIMAL SCIENCE JOURNAL, vol. c. 1-7, 2014, pages 1,4, XP055487364 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019068271A1 (en) * | 2017-10-03 | 2019-04-11 | Bellemed Innovations S.R.O. | DEVICE FOR SEPARATING FLUID BIOLOGICAL MATERIAL, SEPARATION FLOAT AND KIT |
US20200289720A1 (en) * | 2017-10-03 | 2020-09-17 | Bellemed Innovations S.R.O. | Device for separation of fluid biological material, a separating float and a kit |
US11666694B2 (en) | 2017-10-03 | 2023-06-06 | Bellemed Innovations S.R.O. | Device for separation of fluid biological material, a separating float and a kit |
WO2021214159A1 (en) | 2020-04-22 | 2021-10-28 | Cellunite Gmbh | System and method for automated cell processing |
WO2021214162A1 (en) | 2020-04-22 | 2021-10-28 | Cellunite Gmbh | Modular cell processing |
WO2023001910A1 (en) | 2021-07-23 | 2023-01-26 | Cellunite Gmbh | System and method for cell processing |
CN117305077A (zh) * | 2023-09-25 | 2023-12-29 | 成都赛恩吉诺生物科技有限公司 | 一种全封闭式组织解离方法 |
Also Published As
Publication number | Publication date |
---|---|
KR102143286B1 (ko) | 2020-08-10 |
EP3372669A4 (en) | 2019-07-24 |
IL259095A (en) | 2018-06-28 |
PL3372669T3 (pl) | 2021-01-25 |
EP3372669A1 (en) | 2018-09-12 |
ES2837096T3 (es) | 2021-06-29 |
EA201891056A1 (ru) | 2018-10-31 |
IL259095B (en) | 2022-08-01 |
KR20180073688A (ko) | 2018-07-02 |
WO2017078563A8 (ru) | 2018-05-17 |
EA037537B1 (ru) | 2021-04-09 |
EP3372669B1 (en) | 2020-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3372669B1 (en) | Device for isolating cell fractions from human and animal tissues and method for the use thereof | |
US9463203B2 (en) | Methods of using regenerative cells in the treatment of cartilage defects | |
US10967110B2 (en) | System and methods for preparation of adipose-derived stem cells | |
EP2702144B1 (en) | Automated systems and methods for isolating regenerative cells from adipose tissue | |
AU2004260937B2 (en) | Systems and methods for separating and concentrating regenerative cells from tissue | |
US20150152375A1 (en) | Systems and methods for isolating and using clinically safe adipose derived regenerative cells | |
JP6452695B2 (ja) | 骨髄脂肪部分単離のデバイスおよび方法 | |
EP1765980A1 (en) | Systems and methods for isolating and using clinically safe adipose derived regenerative cells | |
EP2980206A1 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
CN111542350B (zh) | 用于制备脂肪来源干细胞的系统和方法 | |
US20190224245A1 (en) | System and Methods for Preparation of Adipose-Derived Stem Cells | |
RU2620304C2 (ru) | Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения | |
Ferroni et al. | Methods to isolate adipose tissue-derived stem cells | |
RU173796U1 (ru) | Устройство для фракционирования жировой ткани и выделения из нее стромально-васкулярной фракции для применения в регенеративной медицине | |
WO2018160096A1 (ru) | Устройство для фракционирования жировой ткани и выделения из нее стромально-васкулярной фракции для применения в регенеративной медицине | |
KR101440754B1 (ko) | 세포 농축형 분리기 및 분리 방법 | |
US20240016851A1 (en) | System and Methods for Preparation of Adipose-Derived Stem Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15907892 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 259095 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201891056 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2018-000300 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 20187015690 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015907892 Country of ref document: EP |